Kodiak Sciences will present emerging data from the Phase 1b clinical study of KSI-301 in treatment-naïve patients with neovascular age-related macular degeneration (wet AMD), Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO) in San Francisco, in an upcoming event, at the Annual Meeting of the American Academy of Ophthalmology (AAO).
Kodiak’s CEO Viktor Perlroth said that the early durability data from patients with wet AMD treated with KSI-301 in are satisfactory, from the Phase 1b clinical study announced last month at The Retina Society Annual Meeting. He said that those data underscored our belief in the potential for KSI-301 to be a leading, next-generation anti-VEGF with a long-interval durability profile.
“We look forward to building on those initial results with Dr. Charles Wykoff’s upcoming presentation at the AAO Retina Subspecialty Day, where new data will be shown on the efficacy, safety and durability of KSI-301 in wet AMD as well as DME and RVO. These are the three diseases most commonly treated with intravitreal anti-VEGF therapies. We look forward to further engaging with the community about the new data and our planning for the clinical development of KSI-301.”
KSI-301 is an investigational therapy built on the Kodiak’s ABC Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing agents.